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INTRODUCTION 
 
 
 Preeclampsia is a multisystem disorder characterised by raised blood 
pressure and proteinuria. It complicates 5-8% of pregnancy and is a major cause 
of maternal and perinatal morbidity and mortality. 
 (ACOG 2002², Sibai et al 1997 (39)  
Traditionally approach of balancing the interests of the mother with those 
of the fetus has been adopted in the management of preterm pregnancies with 
mild preeclampsia. Severe preeclampsia conversely has been delivered without 
delay regardless of fetal consideration. 
With improved methods of monitoring maternal and fetal well being, 
several investigators begun to challenge the traditional view that women with 
severe preeclampsia need be delivered expeditiously. 
 Recent approach advocates conservative management in a selected group 
of women with severe preeclampsia remote from term with the aim of improving 
perinatal outcome without compromising maternal safety. 
 
 
 
 
 
 
 
  
     REVIEW OF LITERATURE 
MINIMUM CRITERIA OF DEFINING PREECLAMPSIA 
 
Preeclampsia is a clinical diagnosis encompassing three elements (committee 
on obstetric hypertension in pregnancy ACOG 1996) 
 
1)  New onset hypertension (defined according to the latest American 
college of obstetricians and gynecology bulletin simply as a blood pressure 
consistently  more than 140/90 mm of  Hg in previously normotensive 
women). 
2)  New onset proteinuria defined as more than 300mg /24hrs or > 2+ on 
a clean catch dipstick in the absence of urinary infection) 
3) New onset significant independent edema. 
The diagnosis of PREECLAMPSIA should be made only after 20 
weeks gestation 
 
.In the past it has been recommended that an increment of 30 mmHg 
systole or 15 mmHg diastolic blood pressure be used as a diagnostic criterion, 
even when absolute values were below 140/90 mmHg. This criterion is no longer 
recommended because evidence shows that women in this group are not likely to 
suffer (Levine 2000, North & Colleagues 1999.(24)) but warrant close 
observation. 
 
 
Conventional mercury sphygmomanometry remains the gold standard for blood 
pressure measurement. Blood pressure should be measured with the women 
seated or at 45º recline, with her feet supported or on the ground, and her arm at 
the level of the heart. The right arm should be used with the cuff of the 
appropriate size. Electronic blood pressure monitors may underestimate the true 
pressure. 
Nowadays it has been recommended that kortkoff phase V be used as a measure 
of diastolic pressure. (Brown et al 1998 ). 
1. K4/K5 difference is smaller in hypertensive than in normotensive pregnant 
women.  
2. K5 is closer to the actual intraarterial pressure, physiologically more 
accurate, is more reliably detected and is reproducible. 
3. K4 has limited reproducibility (shennam et al 1996) 
 
PREECLAMPSIA is classified as either “mild” or “severe”. There is no  
category of moderate Preeclampsia. 
 
 
 
  
 
 
SEVERE PREECLAMPSIA (ACOG) 
 
A diagnosis of severe Preeclampsia should be entertained in women with 
new onset proteinuric hypertension and one or more of the following 
complications 
1)  Symptoms of central nervous system dysfunction, (blurred vision,   
         scotomata, altered mental status, severe headache. 
2)    Eclampsia (seizures and /or unexplained coma) 
3)     Symptoms of liver capsule distention (right upper quadrant or  
         epigastric pain) 
4)    Severe elevations of blood pressure > 160/110 mmHg on 2 occasions at 
least 6hours apart. 
5)    Proteinuria (>5g/24h) 
6)     Oliguria or renal failure 
7)     Pulmonary edema 
8)     Cerebrovascular accident 
9)     Hepatocellular injury (serum transaminase levels > 2times normal) 
10)   Thrombocytopenia (<100000 platelets /mm³) 
11)   Coagulopathy 
12)    HELLP (hemolysis,elevated liver enzymes, low platelets). 
 
 
 
THEORIES ABOUT CAUSES OF PREECLAMPSIA 
1. Immunological mechanism – BARDEQUEZ (3) 
There is immunological resistance to invading trophoblast by maternal immune 
system. Blocking antibodies and T helper cells, interleukins, interferons, growth 
factors play a major role. This results in inadequate trophoblast invasion of 
myometrial spiral arterioles. 
2. Genetic predisposition – CHESLEY & COOPER 1986 (6) 
Susceptibility is by both single gene and multifactorial inheritance. 
a. Women with angiotensin gene variant T235 had increased incidence 
b. There is higher incidence of factor V Leiden mutation in preeclamptic 
patients 
3. Increased pressor response to angiotensinogen II – ABDUL KAREEM 
1961 (1) 
4. Altered vasoactive factors: VOLHARDT 1918 (45) 
(A) Endothelin- 1.  A potent vasoconstrictor produced by endothelium is 
increased. 
(B) NITRIC OXIDE:- A potent vasodilator is decreased.(Chang et al (5) 
(C) Reversal of  PGI2 to TXA2 and vit.E ratio (Wang et al 1991 Walsh 
1985(41) 
(D) Vasoactive maternal factor (VMF) has been imposed to cause the 
endothelial changes involved in the patho physiology of PIH. 
 
 
 
 
 
 
5. Oxidants and Antioxidants 
 
Hubal et al (18) have confirmed that Preeclampsia may have its origin in a 
disturbed oxidation mechanism. Under normal conditions equilibrium is 
maintained by auto oxidants. With increase in severity of Preeclampsia there is 
increase in lipid peroxidase and reduction in auto oxidants. Vit E lipid peroxidase 
cause endothelial damage. 
 
6. Endothelial dysfunction: HAYMAN & ASS 2000 (17) 
Deficiency in trophoblastic invasion of placental blood spiral arteries leads to 
poorly perfused fetoplacental unit. This results in secretion of plasminogen 
activator inhibitor, into the maternal circulation leading to activation of 
endothelial cells to promote coagulation and increased sensitivity to vasopressor 
agents. 
 
Baker and coll 1995 have shown that VEGF levels are increased in serum of PE 
which may activate endothelial cells and release of inflammatory substances. 
 (Dekar & Sibai 1998(8) 
 
 
 
 
 
7. Placental proteins: 
 Corticotropin releasing factor, HCG, Activin A, Inhibin A are said to play a role.  
 
8. Dietary deficiency: DAWSON, KELLY & Coauthors 
Mac Gillivray viewed the evidence for a role of dietary deficiency in pathology 
of PE. It was concluded that when concentration of calcium is low in extra 
cellular fluid, amount of ionic calcium entering cell wall increases making 
vascular smooth muscle more sensitive to excitation. 
 
9. Hyperhomocystinemia: COLLER ET AL  
 Presence of infarcts retroplacentally is said to be cause of elevated levels of 
circulatory homocysteine. This is due to atherosis formed at placental site. 
Elevated levels damage endothelium by H2O2 generation depletes nitric oxide 
mediated detoxification of homocysteine. Elevated levels of factor V increase in 
prothrombin activation.   
  
 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF PREECLAMPSIA 
PRIMARY LEVEL:          
Changes that occur in placenta and placental vascular bed are the two lesions that 
involve spiral arterioles which are the end arteries supplying intravascular space 
(REDEMAN 1991(32))  
a. Relative lack of trophoblastic infiltration of arterial walls during placentation   
     (Bloen et al 1972)  
b. Acute atherosis ( Robertson et al 1963(33))  
c. Magnitude of defective trophoblast invasion of spiral arterioles correlated 
     with severity of hypertensive disorder. 
d. Lipid accumulates first in myometrial cells and then in macrophages   
    (Madzli & Collegues 2000(20))  
 
SECONDARY LEVEL 
I.Renal system 
a) Decreased uric acid clearance, decreased glomerular function, decreased 
renal blood flow, proteinuria. Intrinsic renal changes caused by severe 
vasospasm  
b) Renal pathology : Proteinuria reflects advanced disease associated with 
poor prognosis( Naeye & Friedman 1979 ) Glomerular endotheliosis    
(Sargo et Al 1959 )   
    
c) Urinary sediments reflects renal changes ( Leduc et Al(19) )  
d) Renal clearance of urate decreased ( Chesley & Williams 1945 )  
e) Hypocalciuria ( Taufield et Al 1987(40) ) because of increased tubular 
reabsorbtion  
f) Hyperuricemia ( Pollok et Al 1960 )  
g) Proteinuria ( Meyer & Colleagues 1994 ) Trace or negative proteinuria 
had negative predictive value only 34% in hypertensive women 3+ or 4+ 
proteinuria were positively predictive of severe preeclampsia  in only 36% of 
cases 
II. Cardio vascular system: 
a. Hemodynamic changes:         
Increased arterial sensitivity to angiotensin II      
Increased peripheral resistance  
Decreased cardiac output  
Increased BP 
b. Blood volume 
Hemo concentration 
Blood volume decreased in women with homozygous for T 235 angiotensin 
genotype associated with preeclampsia (Silver & Associates 2001(35))  
 
 
 
 
 
 
   III. Coagulation system  
a. Intravascular coagulation and less often erythrocyte destruction commonly 
in PE and especially eclampsia ( Baker & Cunningham 1999 )  
b. PT, aPTT, plasma fibrinogen level are unneccessary in management of 
hypertensive disorder of pregnancy ( Baker & Colleagues 1999 )  
c. Thrombin time somewhat prolonged in a third of cases  
d. Thrombocytopenia results from platelet activation, consumption and 
increased platelet production. Platelet aggregation is decreased compared 
with the normal increase seen in pregnancy ( Baker & Cunningham1999)  
e. Fragmentation hemolysis: ( Sanchel Ramos 1994(34) ) Increased RBC 
fluidity in women with HELLP 
f. Antithrombin III lowered ( Chang & Coworkers 1992(5) )  
g. Fibronectin elevated ( Bru Baker & Colleagues 1992 ) 
h. Thrombophilias : Clotting factors deficiencies or mutation associated wuth 
early onset of preeclampsia   
    
 IV. Hepatic system:  
a) With severe preeclampsia there is elevation of liver enzymes (Combes & 
Adams 1972 ) 
b) Increased hepatic artery resistance by Doppler sonography ( Ooster Hof & 
Coworkers(28) )  
c) Periportal hemorrhagic necrosis in the periphery of liver ( Barton & 
Colleagues )  
d) HELLP syndrome : Hemolysis, elevated liver enzymes, low platelet    ( 
Deboer & Coworker 1991(9), Pritchard & Associates 1954(30), 
Weinstein 1985(43) )    
 
V. Endocrine system 
a. Increased  plasma levels of renin 
b. Angiotensin II and aldosterone are decreased ( Weir & Colleagues )  
c. Arial natriuretic peptide is increased in women with preeclampsia 
    (Cunningham & Lindheimer 1999(7)) 
VI. Fluid & Electrolyte system  
a. Volume of extracellular fluid manifest as edema in women with severe 
preeclampsia has expanded beyond the normally increased volume that 
characterizes pregnancy 
b. Electrolyte concentration do not differ appreciably in women with   
compared with those of normal pregnancy 
 
 
 
 
 
 
 
 
 
TERTIARY LEVEL  
 
Tertiary systemic effects of preeclampsia secondary to decompensation which 
presents as one of the following features 
 
 1. Eclampsia    2. Laryngeal edema 
 3. Cerebral hemorrhage  4. DIC  
 5. Corneal edema   6. HELLP syndrome  
 7. Retinal detachment  8. Renal cortical necrosis 
 9. Pulmonary edema   10. ARDS 
 11. Hepatic rupture 
 
 
 
 
 
 
 
 
 
 
 
PREDISPOSING FACTORS OF PREECLAMPSIA 
1. Age :  
Young primi < 20 years 
All patients > 30 years Bobrowski & Bottoms 1995 
showed increased incidence of HT & PIH > 35 years 
 
2. Parity :          
Primi have incidence of 11.9% and multi have 4.7% Clinical obs and  gyn. 
The   incidence is 24% in new paternity multipara because of shorter period of  
  Sperm exposure preceding conception 
 3.  Race  
Davis in 1970 found an increased incidence in muslims, jews &arabs 
Africoamerican ethinicity is quoted to have increased incidence by Sibai      
1997, Walker 2000 
 
4.  Social status: 
Women of low social economic status are reported to have greater incidence 
of PIH, PE, Eclampsia. But Duffer & Mac Gillivray –1968 found that  
difference between social classes are small if allowance are made for age, 
parity and levels of antenatal and intrapartum care. Baird and colleagues 
1969 said that incidence was not different among five socioeconomic status. 
 
 
 5. Previous H/O preeclampsia  
 a. The risk of preeclampsia in subsequent pregnancies is higher when it is 
severe earlier and associated with low birth weight 
         b. Risk increases on increasing maternal age and interval between   
pregnancies.     
   Sibai et al studied subsequent pregnancy outcome in women with severe PE in     
   first pregnancy 
Risk of developing eclampsia - 1.4%  
Preeclampsia   -  45.5 %  
         Abruption        -   2.5 % 
   Perinatal mortality       -   5.9%   
Norwegian study showed risk of 13.1% of PE in second pregnancy.  
 
6. Family history:          
Severe preeclampsia, eclampsia have a familial tendency. There is three fold 
increase of preeclampsia and four fold increases severe PE.Chesley et al(6) 
found 26% incidence of PE in daughters.  Lie et al found odds ratio 2.23 in 
sisters especially full sisters. 
Risk Over all Mother with PE Sisters with PE
Nullipara 5-6% 20-25% 35-40% 
Multipara 0.25-5% 1-2% 2-4% 
    
 
 
 
 
 
7. Pregnancy associated: Early onset       
a. Twin gestation: Four fold increased risk Incidence of PE 25.3% this is due to 
hyperplacentosis with increased placental hormone secretion relative placental 
ischemia or immunological reaction to the large placental mass  
b. Molar pregnancy: Confined to large rapidly growing moles in which    the 
incidence of PE is 70% (Page 1939(29)) .  With small slowly growing moles 
there is no increased incidence of PE. 
c. Hydrops fetalis : Increased incidence due to hyperplacentosis. 
d. Congenital malformations: In pregnancies complicated by triploidy, the 
risk of developing PE or hypertension in second trimester is 35% due to 
placentomegaly. 
8. Urinary tract infection:  
UTI resulting in an increased production of inflammatory products, cytokines, 
free radical species and proteolytic enzymes causes endothelial dysfunction  
(Schieve et al)    
 
 
 
 
 
 
9. Underlying disorders: 
a. Chronic hypertension is encountered in approximately 30 – 40 %  
of early onset severe PE . 
b.Underlying renal disorder : 20%  have superimposed PE 
c. Obesity, insulin resistance & diabetes  Stone et al – BMI is an 
independent   risk factor of severe PE  
  i. Obesity correlated with hypertension by expanded blood volume, Cardiac 
output to meet   the increased metabolic demands. 
ii. Obesity- dyslipidemia- delivery of free fatty acids to tissue, higher cholesterol 
/ TG ratio, insulin resistance & hyperinsulinemia.   
 iii.Adipocytes release TNF alpha thereby involved in aggravating cytokine 
mediated oxidative stress. 
  iv. Insulin resistance/ hyperinsulinemia associated with increased sympathetic 
activity and/or increased tubular sodium reabsorption thereby producing direct 
hemodynamic changes.           
V. Overt DM – 30% PE especially when vascular changes present. Khan & 
Daya showed odds of having PE increased by 20% per nmol/L increase in 
plasma glucose level. 
 
 10. Smoking:  
 Decreases incidence of PE since it causes a significant reduction in HCG and 
estradiol level due to direct effect on the placental function (Bernstein et al 
1989)   
 
 
 
Management objectives in severe preeclampsia  
  There is no preventive therapy against preeclampsia available at 
present even though aspirin, calcium magnesium,fish oil have been tried 
severe preeclampsia is associated with maternal complications like HELLP, 
eclampsia, cerebral manifestations, abruption, fetal complications like 
IUGR, IUD, preterm delivery. As termination of pregnancy remains the only 
cure, the primary objective in the management of severe preeclampsia is to 
effect timely delivery in order to 
• Prevent maternal morbidity and mortality 
• Deliver a baby in an optimal condition, thereby minimizing 
perinatal morbidity and mortality. 
In all circumstances, the well being of the mother is primary  
In some circumstances, delays seriously jeopardize the well being of the 
mother, fetus or both. 
Williams obstetrics says "we are reluctant to advice clinician that is safe to 
expectantly manage ……… such women are not managed expectantly at 
Parkland hospital”. 
In some situations, delay of delivery will benefit the mother fetus and both. 
Such an approach has been advocated by research workers in various parts 
of the world. 
  
  
 
 
RANDOMIZED CONTROLLED TRIALS FOR EXPECTANT VS 
AGGRESSIVE MANAGEMENT OF SEVERE PREECLAMPSIA 
REMOTE FROM TERM 
S.No TRIAL STUDY 
GROUP 
FETAL OUTCOME MATERNAL 
OUTCOME 
1 Odendaal et al 
In 1990(20) 
38 patients 
28-34 weeks 
GA 
Babies in NICU 
11% vs 35%) 
Neonatal omplications 
(33%vs75%) 
No increase in 
complications 
2 Sibai et al 
1994(39) 
95 patients 
28-34 weeks 
of GA 
Lower No.of days in 
NICU (20.2days vs 36.6 
days ) 
Lower incidence of 
RDS (22.4 % vs 50%) 
Average birth weight 
being higher ( 1622gms 
Vs 1233gms). 
 
No increase in 
complications 
 
 
 
 
 3. 
 
HALL et al 
2000(14) 
 
340 women 
28 -34  weeks
 
 
 
------ 
 
One  maternal 
death 
8% major 
complications 
4.  
Visser et al 
1994(38) 
50 patients 
25 to 35 
weeks 
 
Perinatal mortality 7% 
in study group 
14% in control group 
 
 
 
 
5. Moodley et al 
1993(21) 
50 patients 
GA < 32 
weeks 
Perinatal mortality 
27% in 30-32 weeks 
 
20% maternal 
complications 
6. Visser and 
wallenburg  
1995(38) 
250 women 
< 34 weeks 
50% severe 
preeclamptic
50% HELLP
Perinatal mortality 
27% 
5% placental 
abruption 
3 women 
developed 
eclampsia 
7. Railton 
A,Allen DG 
1987(31) 
56 Women 
24 -32 weeks 
 
 
24.5% perinatal 
mortality 
19% small for 
gestational age 
 
23.2 %major 
complications 
 Labour induction 
 
Labour is induced by either misoprostol or cerviprime in both the groups. 
Misoprostol is prescribed as a intravaginal dose of 50 mcg at 4 hrs interval which 
can be repeated for 4 times. 
 Sahin 2000 has concluded that intravaginal Misoprostol in an equally effective 
and safe method of induction of labour in patients with preeclampsia and normal 
pregnant women. Patients went in labour earlier within 12 hours, median time 
from induction to delivery being 14 hours. Rate of vaginal delivery was 
significantly higher in the Misoprostol group 82% than that of inducing with 
oxytocin. 
As there was no significant difference between Misoprostol and oxytocin with 
regards to APGAR scores and NICU admissions we advocated Misoprostol 
mostly. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
                 AIM OF THE STUDY 
 
 
1. To compare the merits and demerits of aggressive and expectant    
      management of women with severe Preeclampsia remote from  
      term 28 – 34 weeks.  
2. To determine which is more beneficial by comparing perinatal and 
maternal outcome by statistical analysis by Chi square test  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
Study design    : Prospective 
Study period   : Sep.2003 – Aug 2005 
Sample:  
Group A: - Patients of severe PE remote from term 28 34 weeks treated 
aggressively that is glucocorticoid therapy followed by delivery in 48 hrs. 
 All patients who delivered within 96 hrs of admission were noted. 
Group B: - Patients of the same group treated expectantly i.e glucocorticoid 
therapy, intensive maternal and fetal monitoring followed by delivery only for 
specific maternal or fetal indication beyond 96hours. 
Sample size :    
97 patients of group A who delivered after 48hours of glucocorticoid therapy and 
92 patients of groupB were compared. 
  
 
 
 
 
SELECTION CRITERIA 
 
 Inclusion Criteria : 
 All subjects had  
 1) GA 28 - 34 weeks. 
 2) Severe pre eclampsia defined as 
i) Blood pressure > 160/110 with proteinuria> 2+ 
 ii. Blood pressure > 150/100 with proteinuria >3+  
 iii.Blood pressure > 140/90 with proteinuria with c/o Headache or oliguria 
  
Exclusive Criteria :   
1. Women with medical complications 
2. Rupture of membrane  
3. Preterm labour 
4. Multifetal gestation 
5. Fetal compromise/ fetal death 
6. Platelet count < 1, 00,000/ Mic.L or HELLP 
7.Eclampsia 
8.Fetal congenital mal formation  
Babies born without completing steroids are not compared with exp. Group 
 
 
 
 
 
 
GUIDELINES FOR EXPECTANT MANAGEMENT 
1. All patients are observed in Labour room atleast for 24 hours to 
 determine their  eligibility for expectant management. 
2. Intravenous magnesium sulphates for seizure prophylaxis for selected 
patients.Glucocorticoid are given to improve fetal outcome. 
3. Antihypertensive for BP control. 
4. Complete Blood count, Platelet count, urine protein, serum creatinine, 
serum uric acid, AST, LDH. 
5. Limited oral intake for the first 24 hours and IV fluids at the rate of 100 – 
125 ml/ hr within 24 hours. 
After 24 hours  
MATERNAL      FETAL 
1. BP measured every 4 to 6 hours  1. We do NST daily 
2. Platelet everyday     2. USG for fetal weight  
3. SerumAST, creatinineeveryotherday         and IUGR  weekly 
4. Serum Uric Acid biweekly 
5. Oral antihypertensive drugs to control BP systole in the range of 130 –    
  150 mmHg, diastole in the range of 80 – 100 mmHg 
6. Daily Weight, Daily Urine albumin, Gravidogram. 
7. Retinal changes. 
 
 
 
 
 
Then later 
 1. Headache in preeclamptic women are treated with analgesic and bed rest. 
2. If there is no resolution within 6 hours, head ache is severe, BP is controlled 
meticulously and IV magnesium sulphate is started. 
3. If the headache persists then decision is made for delivery.    
What to expect of expectant management? 
At any time during the concerned period of prolonging pregnancy, 
contraindications to expectant management appear, we terminate the pregnancy 
may be by vaginally or abdominally. 
MATERNAL INDICATIONS 
1. Uncontrolled severe BP  persistently > 160 mmHg systole & >110 mmHg   
       diastole despite maximum dose of the antihypertensive medication for four    
       days   
2.    Eclampsia 
 3.   Platelet count <1, 00,000/ mic ml 
4.   AST or ALT >2 times of upper limit of normal value with epigatric pain or   
      right upper quadrant tenderness 
 
 
 
 
5    Pulmonary edema 
6. Compromised renal functions- rise in serum creatinine of 1 mg/dl over 
baseline levels. 
 7. Abruptio placenta 
8.  Persistent severe head ache or visual changes   
Guidelines as adopted as in University of Tennessee, Memphis 
 
FETAL INDICATIONS        
If any one or more present like  
1. Repetitive late or severe variable decelerations 
2. AFI <2cm 
3. USG estimated fetal weight < 5 th percentile & reverse umbilical artery 
diastolic flow. 
TERMINATION 
a.LABOUR INDUCTION: 
1. MISOPROSTOL 
2. Cerviprime gel to improve bishops score before induction of labour in      
   the absence of  fetal distress. May or maynot need augementation 
b.ABDOMINALLY: 
By LSCS  
 
 
 
 
 
 
 
GUIDELINES FOR AGGRESSIVE TREATMENT: 
1. All patients are observed in labour room. 
2. Intravenous magnesium sulphate given to selected patients for seizure 
prophylaxis. 
3. Glucocorticoid therapy given for improving fetal outcome followed by  
          delivery in 48 hrs. 
4. Antihypertensives  for BP control, blood investigations done as like  
         that of the expectant management. 
5. Ultrasonogram for fetal well being .Then labour is induced either by 
misoprostol, cerviprime may or may not be augmented with syntocinon 
infusion  
 
INTRAPARTUM MANAGEMENT 
      
Preeclamptic women are at higher risk of developing convulsions during labour 
as compared to normotensive women, highest being in severe preeclampsia  
remote from term, those with cerebral manifestations, HELLP syndrome. 
 
 
 
 
1. Hence if not initiated with MgSO4, it should be started in labour in 
selected cases.  
2. Once cervix becomes favourable, oxytocin augmentation be given. 
3. If it is unripe, Caesarean section is to be considered because of higher 
incidence of complications like abruption, fetal distress. 
 
4. ANALGESIA 
1. Provided by intermittent use of small dose of 25-50 mg of parentral 
pethidine or segmental epidural analgesia. 
2. Local infitration or epidural in vaginal delivery. 
3. Continuous epidural or balanced general anaesthesia used for caesarean 
patients. 
 
5. Input and output monitoring 
Hourly urine output. 
Fluid restricted to 150 ml / hr. 
If oliguria say <100ml per 4 hrs, fluids & MgSO4 reduced accordingly. 
 
6. Antihypertensive therapy.  
                          Goal is to maintain systole 140 –150 systole and diastole 90-100 mm Hg. 
And not to reduce the mean arterial pressure by more than 20% from 
baseline value. 
 
 
 
 
 
POSTPARTUM MANAGEMENT 
 
1. Intensive monitoring done for 2-4 days. Vitals, reflexes, input output 
monitored. 
2. BP control 
3. Prophylactic anticonvulsives not given. 
4. Patient is seen at weekly intervals until her BP is normal without 
medications. 
5. If this change does not occur by 6 weeks work up for hypertension made 
 
 
 
OUT COME 
Parameters like prolongation of pregnancy, perinatal outcome, and maternal 
morbidity were evaluated. 
 
 
 
 
 
 
DATA ANALYSIS 
From September 2003 to august 2005, women with severe preeclampsia were 
noted. Among 259 patients of severe preeclampsia remote from term 28to 34 
weeks ,167 patients got terminated with in 96 hours of admission . 
 
Among them 97 patients who got full dose of steroids were compared with 
the remaining 92 patients who got terminated after 96 hours of admission. 
Participants with similar characteristics were assigned. 
 
Maternal age, parity, gestational age, initial systole and diastole, dose of 
antihypertensives were comparable in both the groups. 
Principal measures like 
a. Maternal outcome  
b. Mode of delivery and their indication 
c. Perinatal out come were analysed in both the groups 
 
 
 
 
 
 
 
 
 
 
INCIDENCE IN STUDY PERIOD 
Total Number of Deliveries 26,500 
Mild  Preeclampsia 10% 
Severe Preeclampsia 1% 
Eclampsia0.04%  
TABLE 1 
MATERNAL AGE 
AGE(YRS) AGGRESSIVE  EXPECTANT TOTAL 
16-19 10 ( 10.3% ) 5 ( 5.4% ) 15 ( 7.9% )  
20- 24 23 ( 23.7% )  22 ( 23.9% )  55 ( 29.1% ) 
25- 29  28 (28.8 %) 32 (34.7%) 60 ( 31.7 % )  
30-34 32 ( 39.1% ) 37 ( 33.6% ) 63(33.3%) 
35-40 4 ( 4.1% ) 2 ( 2.1 % ) 6 ( 3.1% ) 
TOTAL           97 92 189 
  
>60% of patients were around 25-34 years of age 
 
 
 
 
 
 
 
TABLE 2 
GRAVIDITY 
GRAVIDITY AGG.(97 ) EXP.(92) TOTAL(189) 
PRIMI 60 ( 61.8% ) 62 (67.3%)  122(64. 5%) 
SECOND  12 ( 12.3% ) 16 ( 17.3 % ) 28 ( 14.8% ) 
THIRD 13 (13.4% ) 12 ( 13 %)  25 ( 13.2% ) 
FOURTH 8 ( 8.2% ) 2 ( 2.17% ) 10 ( 5.2% ) 
FIFTH 4 (4.1% )            - 4 (2.1% ) 
Around 64.5% of Patients were primis 
 
 
 
TABLE 3 
GESTATIONAL AGE 
GA – WEEKS AGG.(97) EXP.(92) TOTAL(189) 
28-30 34(35.0%) 27(29.3%) 61(32.3%) 
31-32 39(42.3%) 39(42.3%) 78(41.3%) 
33-34 24(24.7%) 26(28.2%) 50(26.4%) 
   
Mean GA on admission was 31 weeks 
 
 
 
 
 
 
TABLE 4  
ANALYSIS OF PAST OBSTETRIC HISTORY 
 PREECLAMPSIA AGGRESSIVE (37) EXPECTANT (32) TOTAL (69) 
Past History 
Mild 
Severe 
Eclampsia 
Abruption 
15 (40.5%) 
10 (27%) 
3 (3%) 
1 (2.7%)  
1 (2.7%) 
10 (31.2%) 
9 (28.1%) 
1 (3.1%) 
      - 
       - 
25(36.2%) 
19 (27.5%) 
4 (5.8%) 
1 (0.01%) 
1 (0.01%) 
Not known /  
No Previous  history 
 
22 
 
22 
 
44 (63.7%) 
 
36% of patients had recurrent Preeclampsia 
 
 
 
 
 
 
 
 
 
 
TABLE 5  
ANALYSIS OF BODY MASS INDEX 
BMI AGG EXP TOTAL 
<25 20(20.5%) 35(38%) 55(29.1%) 
25-30 28(28.9%) 25(27%) 53(28%) 
31-35 25(25.7%) 22(24%) 47(24.8%) 
36-40 18(18.56%) 8(8.75%) 26(13.75%) 
>40 6(6.18%) 2(2.1%) 8(4.2%) 
 
Around 43% of patients had BMI >30 
           18% of patients had BMI >35 
  Mean BMI 27.4 
TABLE 6 
ANALYSIS OF FAMILY HISTORY 
Aggressive Expectant F/H/O 
P 50 M37 T 97 P  62 M  30 T 92 
 Not known  
/no history  
50 29 79 (81.4%) 54 27 81(88%) 
Mother PE 4 2 6(6.18%) 2  -  2(2.17%) 
Sister PE 6 6 12(12.37%) 6 3 9(9.78%) 
 
4.23% of patients had mother withpreeclampsia 
11%of patients had sister with preeclampsia 
 
 
 
TABLE 7 
ANALYSIS OF BLOOD PRESSURE SYSTOLE 
Initialsystole mmHg Agg. Exp. Total 
140-149 30(30.9%) 29(31.5%) 59(31.2%) 
150-170 48(49.4%) 55(59.7%) 103(54.5%) 
>170 19(20.1%) 8(8.69%) 27(14.3%) 
 
Around 54.5% of patients had systolic BP 150-170 mmHg  
Mean being 160mmHg 
 
 
  TABLE 8 
ANALYSIS OF BLOOD PRESSURE   DIASTOLY 
Initial Diastole mmHg AGG. EXP. TOTAL 
90-100 25(25.8%) 30(32.6%) 55(29.1%) 
101-110 37(38.2%) 39(42.4%) 76(40.2%) 
111-120 20(20.6%) 16(17.4%) 36(19.0%) 
>120 15(15.4%) 7(7.6%) 22(11.7%) 
 
40% of patients had diastole 101-110 mmHg  
Mean being 106mmHg 
 
 
 
 
 
  
TABLE 9 
ANALYSIS OF ANTIHHPERTENSIVE DRUGS 
                    ALPHA METHYL DOPA 
Dose(mg) Agg.         %   Exp .      %   Total     % 
500-750      17          (17.5)    15        (16.3)   32   (16.9) 
      750-1000       25          (25.8)      38       (41.3)   63    (33.3) 
   1000-1500       45           (46.4)     32        (34.8) 77    (40.7) 
      1500-2000 10           (10.3) 7            (7.6)    17(9.0) 
 
About 40.7% patients were given 1000-1500 mg of alpha methyl dopa per day 
 
                                                    TABLE 10 
NIFIDEPINE DOSAGE 
Dose (Mg) Agg       (%) 
 
Exp (%) Total 
 
10 –15 20 (20.6) 25 (27.2)  45 (23.8) 
15-20 42(43.4) 40(43.5)  82(43.4) 
 20-25 15(15.5)  24(26.1)   39(20.6) 
25-30  20(20.6)  3(3.2) 23(12.2) 
 
About 43.4% patients  were given 15-20 mg per day of nifedipine 
 
 
  
 
          TABLE 11 
              INITITATION OF MAGNESIUM SULPHATE 
 
Intial Diastole Aggressive(97) Expectant  (92) Total 
>120 (22) 15 (15.4%) 7(7.6%) 22(11.6%) 
111-120 (36) 20(20.6%) 16(17.4%) 36(19%) 
101-110(76) 27(27.8%) 22(24%) 49(25.9%) 
90-100 (55) 10(10.3%) 11(12.9%) 21(11.1%) 
Not given 25(25.8%) 36(39.1%) 61(32.2%) 
 
128 patients were given. Magnesium Sulphate 
All 58 patients whose diastolic BP > 110 got Magnesium Sulphate 
 
                         TABLE 12 
                RETINAL CHANGES 
FUNDUS AGG.(97) EXP.(92) TOTAL(189) 
Normal 78(80.4) 84(91.3) 162(85.7) 
GR I HTR 16(16.5) 8(8.7) 24(12.7) 
GR II HTR 3(3.1) - 3(1.6) 
 
85.7% them had normal fundus 
  
 
 
                               TABLE 13 
                MATERNAL OUTCOME 
Aggressive(97) Expectant(92) Complication 
AP IP PP T AP IP PP T 
Abruption 2 3 - 5(5.15%) 5 3 - 8(8.7%) 
HELLP/DIC 2 - 1 3(3.1%) 1 2 1 4(4.3%) 
Eclampsia _ - - - - - - - 
Renal 
failure(dialysis) 
_ - - - - - 1 1(1.1%) 
Pul.edema - 1 - 1(1%) 1 1 1 3(3.3%) 
ARDS - - 1 1(1%) - - - - 
Cerebral edema - - - - - - 1 1(1.1) 
Maternal death - - - - - - - - 
Total 4 4 3 10(10.3%) 7 6 4 17(18.4%) 
 
18.4% of major maternal complications occurred in expectant while 10.3% in 
aggressive. Though slightly higher, tackled well by anesthetist & ICU, indicating 
institutional supervision of expectant management. 
 Chi square value = 2.57  
Degree of freedom = 1 
It was found to be statistically not significant. 
 
 
 
 
 
 
                                           TABLE 14 
                                          LABOUR INDUCTION 
Aggressive (97) Expectant(92) Mode 
Primi Multi Total Primi Multi Total 
Misoprostol(M) 39 25 64(66%) 25 10 35(38%) 
Cerviprime(C) 6 3 9(9.28%) 10 2 12(13%) 
M/C+synto aug. 10 5 15(15.5%) 11 2 13(14.1%) 
Not induced due to 
mat ,fetal cause 
5 4 9(9.3%) 16 16 32(34.8%) 
 
Labour was indued in 52% of our study by misoprostol. 
16 multies of expectant group were not induced due to post caesarean pregnancy 
 
                                          TABLE 15 
                                DURATION OF LABOUR 
Aggressive(97) Expectant(92) Duration 
in hrs Primi(55) Multi(33) Primi(46) Multi(14) 
4-7 11 9 10 4 
8-11 28 20 25 7 
12-15 10 3 9 3 
16-19 6 1 2 - 
 
Most of them delivered in 8-11 hours after induction 
 
 
 
 
                                        TABLE 16 
                             MODE OF DELIVERY 
Aggressive(97) Expectant(92) Mode 
Primi Multi Total PN 
Loss 
Primi Multi Total Pnloss 
Vaginal 50(83.3%) 32(86.5%) 82(84.5%) 52 38(61.2%) 10(33.3%) 48(52.17%) 16(33.3%)
LSCS 10(16.7%) 5(13.5%) 15(15.5%) 2 24(38.7%) 20(66.6%) 44(47.82%) 12(27%) 
Total 60 37 97 54 62 30 92 28 
 
 As salvagability and fetal weight were lower in aggressive group, vaginal       
delivery preferred. 
Increase in LSCS in exp. was due to post caesarean pregnancy in them. 
27% of patients delivered by LSCS lost their babies.  
Chi square value is 20.16  
  DF is 1. Significant at 0.001 (p< 0.001) 
  PN Loss indicates perinatal loss 
  
 
              
      
 
 
 
 
 
                                                   TABLE 17 
                             INDICATIONS OF LSCS IN EXP.GROUP 
Indication Primi (24) Multi (20) Total (44) Perinatal loss (28) 
Post LSCS - 16 (80%) 16(36.4%) 5(31.2%) 
Nonreassuring CTG 5 (20.8%) 2(10%) 7(15.9%) 4(57.1%) 
Malpresentation 5 (20.8%) --- 5(11.3%) 1(20%) 
Fail to progress 
/unfavourable Cx 
14(58.3%) 2(10%) 16(36.4%) 2(12.5%) 
 
80% of multis were post caesarean pregnancies. 
42.8% of perinatal loss occurred after LSCS  
  
                 INDICATIONS OF LSCS IN AGG. GROUP 
Indication P(10) M(5) T(15) PN loss 
Nonreassuring CTG 5 4 9 1 
Fail to progress 3 1 4 - 
Abruption 2 - 2 1 
 
13.33%of patients lost their babies by LSCS 
P –primi, M-multi,T-Total  
 
 
 
 
                                      TABLE 18  
      INDICATION OF TERMINATION IN EXP. GROUP 
MATERNAL INDICATION 
Indication P ( 60) M (32) T (92) Pn loss 
Abruption 3 2 5(5.4%) 4 
Imminent sym. 28 10 38(41.3%) 8 
Uncontrolled BP 5 6 11(12%) 3 
Compromised 
renal function 
1 3 4(4.3%) - 
Pul edema 1 - 1(0.01%) 1 
Eclampsia - - - - 
Total 39 20 59(64.1%) 16(27.1%) 
 
64.1% of patients terminated by LSCS for maternal indication most common 
being imminent sym.  
27.1% of patients lost their babies. 
There was 57.2% of  perinatal loss in patients who were terminated for maternal 
indication  
 
 
 
 
 
 
 
 
 
                                              TABLE 19 
                     FETAL INDICATIONS FOR TERMINATION 
 
Fetal cause P M Total Pnloss 
Oligohydramnio 10 6 16(17.3%) 3 
 Persistent Late 
deceleration 
5 2 7(17.6%) 4 
IUGR<5th 
percentile 
6 4 10(10.9%) 5 
Total 21 12 33(35.9%) 12(36.3%) 
  
35.9% of patients got terminated due to fetal indication, most common among 
being oligohydramnios. 
Among them 36.3% of pts lost their babies. 
42.8% of perinatal death occurred in patience who were terminated for fetal 
indications. 
P  =  primi 
M  =   multi 
Pn loss =  perinatal loss 
 
 
 
 
                                             TABLE 20 
                                      FETAL OUTCOME 
Aggressive Expectant Born 
P M T P M T 
Totalbirth 60 30 97 62 30 92 
       
Live born 46 31 77(79.3%) 58 28 86(93.5%) 
Still birth 14 6 20(20.6%) 4 2 6(6.5%) 
Neonatal D 24 10 34(35.1%) 14 8 22(24%) 
Perinatal D 38 16 54(55.7%) 18 10 28(30.4%) 
 
Perinatal loss in agg. 55.7% 
  Inexp. 30.4% 
  These perinatal loss include still birth and early neonatal death 
For live born, 
Chisquare value -7.91, Degree of freedom-1, significant at 0.005% P (<0.005)  
For perinatal loss, 
Chisquare value -2.24, Degree of freedom-1, significant at 0.001% P (<0.001) 
 
 
 
 
 
 
 
 
                                     TABLE 21 
               BIRTH WEIGHT SPECIFIC DEATH 
Aggressive Expectant Birth wt(kg) 
Born Death Born Death 
< 1 10 10(100%) 2 2(100%) 
1.0-1.25 27 21(78.4%) 16 12(75%) 
1.26-1.5 35 16(46%) 27 10(37%) 
1.51-1.75 18 6(33%) 30 3(10%) 
1.76-2 4 1(25%) 7 1(14%) 
2.1-2.25 3 - 7 - 
2.25-2.4 1 - 3 - 
 
Maximum birth wt born was 2.4kg 
51% of expectant group and 27% of aggressive group had babies birth weight 
more than 1.5 kg. Average birth weight was 1.58 kg  
Chisquare value -13.69 Degree of freedom 2 
Significant at 0.005 %( P<0.005) 
 
 
 
 
 
 
 
 
 
                                  TABLE 22 
GESTATIONAL AGE SPECIFIC PERINATAL MORTALITY 
Aggressive Expectant GA(wks) 
Born Death Born Death 
28-30 34 26(76.5%) 29 18(62%) 
31&32 38 18(47.4%) 24 8(33.3%) 
33&34 25 10(40%) 38 2(5.3%) 
Total 97 54(55.7%) 92 28(30.4%)
  
As gestational age gets prolonged, perinatal death is lesser both agg.& exp. 
giving  5.3% death in 32-34wks in exp. 
 Mean Gestational age 32 weeks  
 
 
 
 
 
 
 
 
 
 
 
                                               TABLE 23  
       PROLONGATION OF PREGNANCY IN EXP. GROUP 
Latency interval(days) Cases Pnloss 
<5 24(26%) 14(58.3%) 
5-8 32(34.8%) 8(25%) 
9-12 27(29.3%) 4(14.8%) 
12-20 7(7.6%) 2*(28.5%) 
>20 2(2.17%) - 
Total 92(100%) - 
 
* two cases were abruption 
Maximum prolongation of pregnancy was 24 days& median  
prolongation was 10.5days.Mean being 8.6 days  
 
PERINATAL OUTCOME IN PREGNANCIES LATENCY <96 HOURS 
Latency interval (hrs) Cases Pnloss 
<24 48 39(81.25%) 
24-48 32 24(75%) 
49-72 75 44(58.6%) 
73-96 22 10(45.4%) 
 
97 patients who were terminated more than 48 hour of steroids were compared in 
our study. 
 
 
 
 
 
                       TABLE 24 
NEONATAL HOSPITALISATION 
Live babies Aggressive Expectant  
Admission to NICU 77(100%) 79(92%) 
Neonatal deaths 34(44.2%) 22(27.9%) 
<5  2(2.6%) 25(31.6%) 
5-10 18(23.4%) 17(21.5%) 
Survival hospital 
stay(days) 
11-15 10(13%) 9(11.4%) 
 >15 13(16.9%) 6(7.6%) 
Total survival 43 57+7=64 
Survival rate 55.8% 74.4% 
 
Mean stay of hospitalization is eight days in expectant group 
Whereas in aggressive group it is 14 days. 
 
 
 
 
 
 
 
 
 
                   DISCUSSION 
Incidence of Preeclampsia is 5 to 8% according to ACOG 2002. 
• Incidence of Preeclampsia in IOG is 10% 
 Severe Preeclampsia contributes 1% of all deliveries. There were 259 cases of 
severe Preeclampsia remote from term 28 to 34 weeks in our study period. 189 
patients got full dose of steroids and they were assigned as aggressive 
and expectant group in their management. 
 • 64.5% of patients were Primi… 
Majority of cases say 75 to 80% occur during the first pregnancy.(clinical 
obstetrics and gynecology journal volume 42) 
      
• 60% patients were in age group 25 to 34 yrs. 
Young patients <20 & patients > 30 yrs said to have increased incidence of 
Hypertension and Preeclampsia.( AMJ of obstet gynecol 1993)  
       
• 18% patients had BMI > 35 
 36% patients had Recurrent Preeclampsia 
4.23% patients had mother with Preeclampsia 
11% patients had sister with Preeclampsia. 
 
 
 
Likelihood of developing Preeclampsia is increased in according to  
 BJ OG October 2003. 
1. Primi 
2. Age .> 30 
3. With family history 
4. BMI > 35 
5. Preexisting Hypertension 
                 
 Sibai et al(37) showed risk of developing Preeclampsia in next pregnancy 
being  45.5%. Out of them 21% go for Severe Preeclampsia.              
 
MATERNAL OUTCOME 
Comparisons of major complications in both the groups 
Odendaal et al 1990(26) No increase in complications 
Sibai et al 1994 (39) No increase in complications 
Hall et al 2000 (340 women) No maternal death,  3 required ICU 
1 required dialysis in expectant. 
Haddad B, Deis  S 2004(11) No maternal death or eclampsia.Morbidities 
similar among both groups. 
Railton A, Allen DG 1987(31) 23.2% had increase in major complications 
Our Study, 2005 10.3% in aggressive group 13.6% in expectant 
group. Not statistically significant 
 
 
 
 
MATERNAL COMPLICATIONS VISE 
Study 
 
Abruption 
 
Pulmonary   
Edema 
HELLP/     
ELLP 
Eclampsia Renal   
Failure 
Hall and colleagues 2000 20% 2% 5% 1.2 % 0.3% 
Vissur and Wallenburg 
1995 
5 % --- NA 1.9 % --- 
Murphy DJ and  Stirrat 
GM 2000(22) 
1.5 %  
---- 
21 % 1.4% 1.3% 
Olah KS, 
RedmanCW,Gee H 1993 
 
---- 
 
---- 
 
14.2 % 
 
---- 
 
3.5 % 
Our study 2005  8.7% 3.3% 4.3% --- 1.1% 
 
Our study showed relatively low incidence of abruption and HELLP 
than Hall’s study and renal failure correlating with Murphy’s. 
There was no maternal death or eclampsia in our study. 
 
 
 
 
 
 
 
 
 
 
TERMINATION 
         Indication of Termination shows following distribution in studies. 
  
 
 
 
Most common maternal indication being imminent eclampsia. Our study’s value 
was in between the both studies available. 
 
MODE OF DELIVERY 
Though mode of delivery had no influence on fetal outcome 
LSCS rate was higher in expectant management in all. 
         STUDY   V AGINAL     LSCS 
Hall BR  and Odendaal HJ, 2000(12) 18.5% 81.5% 
Nassar et al    306 patients(23) 48.3% 51.7% 
Murphy DJ, Stirrat M 2000 20% 80% 
Railton A and Allen OG,1987 25% 75% 
Our Study, 2005 52.2% (group B) 47.8% ( group B) 
Our study is similar somewhat to Nassar et al. 
Among 4 patients, complicated by HELLP Syndrome or  DIVC 2 patients had 
coagulopathy  with increased clotting time and bleeding from the surgical 
wounds on table, and they were treated  with platelet transfusion, fresh frozen 
plasma and steroids. 
Study Maternal indications Fetal indications 
Blackwell Sc and others 2002 80% 20% 
Hall DR,Odendaal HJ 2000(12) 55% 45% 
Our study 64.1% 35.9% 
   Third patient who developed symptoms in postpartum period was given 6 units     
   of fresh frozen plasma. 
 One patient developed signs and symptoms of Renal failure in immediate 
postpartum period and she was transferred to GH, taken over by Nephrologists,  
she underwent Peritoneal Dialysis twice and she was discharged alive after 22 
days in a stable condition. Three patients who had compromised renal function got 
settled conservatively. 
 
This situation explains necessity of the intensive care facilities in the management 
of severe preeclampsia. 
Hemodynamic monitoring plays a major role in the treatment and trained persons 
and anaesthetists were available all the time for Central vein cathetarisation and 
monitoring. 
 
 
 
 
 
 
 
   PERINATAL OUTCOME 
        PROLONGATION OF PREGNANCY 
Study Mean Prolongation Of Pregnancy 
Odendaal et al, 1990 7.1  days 
Sibai et al 15.4  days 
Vissur W, Wallenburg , 1995 14 days 
Yang 2, Li R and others , Beijing(46) 11 days (28 to 31 weeks ) 
8     days ( 32 to 33 weeks ) 
Railton and Allen DG, 1987 11.4 days 
Olah KS,  Gee H 1993 9.5  days 
Murphy DJ, Stirrat GM, 2000 14  days 
Mithagen MI ,  Vissur W 2001 14 Days 
This study ,2005 8.6 days 
Median  prolongation of  pregnancy in this study was 10.5  days.Our study       
correlates with three studies among eight. 
 
              PERINATAL   MORTALITY 
Study percentage loss 
Railton A; Allen DG 1987 24.5% 
Odendaal HJ, Pattinson RCL 1987(20) 22.3% 
Hall  DR, 2000 24% 
Beneditti  TJ, Beneditti JK 14.3% 
Murphy DJ, Stirrat GM 2000 30% 
Haddad  B,   Deis S,  2004 10.7% 
This Study 2005 30.4% 
 
   In aggressively managed patients, the perinatal mortality was 55.7% giving  
  overall perinatal mortality 43.3%.Our study correlates with Murphy’s and is       
closer to three other studies. 
 
BIRTH WEIGHT 
 
Study Aggressive Expectant 
Sibai et al , 1994 1.2  kg 1.62  kg 
Our Study, 2005           1.05 kg 1.58 kg 
 
Our study correlates with Sibai et al and 
all other studies showed higher birth weight by expectant management  
 
SURVIVAL RATE 
Study  Aggressive  Expectant 
Sibai  1997             24% 65% 
Hall DR 2000 70%  94% 
Our study 2005 55.8% 74.4% 
             
 Railton  A,  Allen  DG, 1987  showed 100% survival rate of babies born > 30 
weeks in either the groups. 
 Our Study showed higher survival rate in babies of higher Gestational Age and 
with higher Birth weight and it was in between both studies. 
 
NEONATAL HOSPITALISATION 
 
 
AGGRESSIVE
 
EXPECTANT 
 
AGGRESSIVE 
 
EXPECTANT 
 
     Study 
      Admission to NICU Hospital stay 
Sibai et al 1974 100% 76% 30.6 days 20 days 
Olah KS, 1983 64.3% 28.6% >15 days 7.4 days 
Our study 2005 100% 92% 14 days 8 days 
 
Our study showed expectant management babies had highest survival rate and 
lower neonatal complications.In our study admission wwas similar to that of Sibai 
et al study because of the lower birth weight but hospital stay as that of Olah  due 
to improvisation of neonatal  facilities for the past two decade. 
 
 
 
 
 
 
 
 
 
 
  
SUMMARY 
 Severe preeclampsia contributes 1% of all deliveries. 
In our study there were 259 patients of severe preeclampsia remote 
from term. Among them 189 patients who had full dose of steroids were 
compared. 
 Most of them were primis 
 Most of them were in age group 25 to 34 years  
 Mean gestational age on admission was 31 weeks. 
 36% had recurrent preeclampsia. 
 15.8% (29) patients had family history of preeclampsia. 
 Mean body mass index was 27.4. 
 Mean systolic BP 160 mmHg and mean diastolic BP being 106 mmHg. 
 Most of them needed 1000 – 1500 mg of alpha methyl dopa and 15-20mg 
of nifedipine for BP control. 
 Most patient had normal fundus. 
 Major maternal complications were higher in the expectant group, 
proved to be statistically non significant. 
   4 Patients had HELLP 
   8 Patients had ABRUPTION 
 1 Needed renal dialysis in expectant group. There was no Maternal 
death and no eclampsia in both the groups. 
 
 
 
 Most of them delivered by 8-11hrs by inducing labor. 
 65% terminated for maternal indication 35% for fetal indication. 
 LSCS rate was higher in expectant group (47.8% vs 15.5%) But this 
was mainly contributed by post cesarean pregnancy in expectant 
group. 
 Perinatal loss was significantly lower in expectant group 30.4% vs 
55.7% proved to the statistically significant P (<0.001). 
 Perinatal loss is not influenced by cesarean section in expectant group 
as 42.8% perinatal death was contributed by LSCS and 57.2% by 
vaginal  delivery statistically not significant. 
 Expectant group had higher birth weight than aggressive significant. 
51% had birth weight > 1.5kg maximum being 2.4kg 
 Mean birth weight being 1.58kg. 
 Mean gestational age at delivery 32weeks. 
 Mean prologation of pregnancy is 8.6 days. 
 Perinatal mortality was higher in the patients delivered <48hrs of 
steroids. 
 Expectant group had relativety low admission of babies to NICU (92% 
vs 100%), lower mean stay of hospitalization (8 days vs  14 days  ). 
 Babies in expectant group had higher survival rate (74.4% vs 55.8%). 
 
 
CONCLUSION 
 
The conservative approach to the management of severe 
preclampsia remote from term results in a good obstetric outcome 
for most fetuses, in view of  
1. Higher birth weight 
2. Lower perinatal mortality 
3. Lesser neonatal complications 
 
 but this must be balanced against the significant risk of morbidity 
to the mothers. 
 
The success rate of expectant management will depend on both fetal 
gestational age and maternal and fetal conditions at the time of 
hospitalization. Since maternal and perinatal complications are 
significantly increased in these patients, expectant management 
should be carried out in well selected patients only at tertiary 
centers with adequate maternal and neonatal intensive care 
facilities.  
Finally patients with preeclampsia are at increased risk for 
recurrence of preeclampsia in subsequent pregnancies. 
 
 
 
 
 
 
 
PROFORMA 
 
Name :     Gravida: 
Age:      ht :        weight: 
IP No:      BMI: 
Occupation:     LMP: 
       EDD: 
       Blood group: 
       Booked / Not: 
 
Complaints: 
Present H/o:  
Period Of Amenorrhea    Present Pregnancy 
Edema feet      I trimester 
Headache        
Oliguria      II trimester 
Pain abdomen 
Vomiting      III trimester 
Blurring of vision      
Palpitation      Treatment of Preeclampsia 
 
Past H/o: H/o Preeclampsia in previous pregnancy 
Menstrual / Marital H/o: 
Medical / Surgical H/o: H/o Epilepsy, Head injury, Neurological disorder. 
 
Family H/o:           H/o PE in Mother/Sister 
 
Personal H/o:   
 
 
             
General Examination: 
Temp     CVS 
PR     RS 
BP     PUPILS 
EDEMA    CNS 
ANAEMIA    P/A 
 
      P/V 
 
 
INVESTIGATIONS: 
Urine Alb   CHG: Hb  Blood Urea 
Sugar    PCV   Sugar 
Deposits   RBC   Creatinine 
     TC   Fibrinogen 
     Platelets  Uric Acid 
        Electrolytes 
 LFT:     USG:    ECG: 
 
Antihypertensive   Drug:   Dose: 
 
Gravidogram: Date urine alb wt.    SFH       AC        BP  . Imminent symptoms 
 
Magnesium sulphate: Time   Dose    Temp    RR     I/O     knee jerk. 
 
 
 
 
 
 
1. Mode of induction 
2. Indication of termination : Maternal / Fetal 
3. Vaginal delivery / LSCS 
Indication of LSCS: 
4. Latency Interval 
5. Baby alive/dead 
Term/preterm 
Cried/not 
Birth weight 
Distress/Not 
Admitted / not 
6. Intrapartum / Postpartum complications 
7. Follow up: NICU stay 
Neonatal complications 
Discharged alive / not. 
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